1. Switzerland Stocks

  2. •

    Financial Services

  3. •

    Asset Management
BB Biotech AG

BB Biotech AG

BBAGF
BB Biotech AGUS flagOther OTC
- -
USD
- -
- -
- -
- -
(- -)

Recent

price

- -

P/E

ratio

- -

div

yld

- -

ROIC.AI

Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
Invalid Date
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
-142
-58
377
938
1,476
659
-796
693
-466
685
699
-396
-351
-200
82
587
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-146
-65
368
932
1,470
653
-802
688
-471
677
691
-405
-358
-207
76
578
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
140
145
135
90
30
160
205
95
185
150
63
355
363
305
118
- -
LT Debt
1,235
1,002
1,234
2,119
3,493
3,978
3,003
3,539
2,885
3,393
3,888
3,283
2,686
2,323
2,286
2,779
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.02%
-5.46%
21.54%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-50.63%
62.51%
661.71%
Sales/Revenue/Turnover
-55.95%
52.13%
613.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available
Similar Companies
Sprott Junior Copper Miners ETF (COPJ)
Kodex MSCI Momentum (275280.KS)
American Funds Washington Mutual C (WSHCX)
Virtus KAR Mid-Cap Growth Fund A (PHSKX)
Third Point Investors Limited (TPNTF)
VI Focus ESG Leaders150 ETF (285690.KS)
Business
BB Biotech AG (Ticker: BBAGF) is a Switzerland-based investment company focused on publicly listed biotechnology firms developing and commercializing innovative drugs in areas such as oncology, neurological disorders, orphan diseases, metabolic diseases, cardiovascular conditions, infectious diseases, autoimmune diseases, and emerging technologies including RNA platforms, cell therapies, and gene therapies. The company maintains a concentrated portfolio of 20 to 35 holdings, with major positions as of December 31, 2024, including Argenx (13.7%), Ionis Pharmaceuticals (10.0%), Neurocrine Biosciences (9.4%), Intra-Cellular Therapies (7.6%), Revolution Medicines (7.2%), Vertex Pharmaceuticals (7.2%), Alnylam Pharmaceuticals (6.7%), and Incyte (5.6%); it targets mid- and small-cap biotech companies offering substantial therapeutic and economic potential while incorporating ESG criteria in its investment decisions. Shares trade on the SIX Swiss Exchange and Frankfurt Stock Exchange, providing investors access to this high-growth sector. Founded in 1993 and headquartered in Schaffhausen, Switzerland, BB Biotech AG operates globally with a focus on U.S.-centric investments given the concentration of biotech innovation there, supplemented by opportunities in Europe and other regions. Recent strategic developments include an ongoing portfolio reallocation announced in October 2024 to sharpen focus amid market volatility, which progressed into 2025 with Q1 results reflecting heightened concentration on high-conviction holdings; in November 2024, the company increased its stake in Molecular Templates Inc. by acquiring 156,424 shares at $0.61 each, bringing total ownership to 904,001 shares to bolster exposure to innovative cancer therapies. In July 2024, BB Biotech appointed a new head of its investment management team to support evolving market dynamics. The company reported strong financial performance in 2025, including a CHF 106 million net profit for the first nine months (as of October 2025), portfolio outperformance versus the Nasdaq Biotech Index in Q2 and Q3 2025 driven by sector recovery signals, and inclusion in the SPI ESG Index in September 2025; it also published its 2024 Annual Report in February 2025, proposing a dividend and positioning for structural biotech recovery.